Entering the golden age for antibody-drug conjugates in gynecologic cancer

“We are optimistic that the incorporation of ADCs into the treatment of aggressive tumors and treatment refractory gynecologic cancers will improve quality of life and survival outcomes in our patients.” Credit: 2024 Greenman et al. “We are optimistic that the incorporation of ADCs into the treatment of aggressive tumors and treatment refractory gynecologic cancers will […]

Jul 13, 2024 - 04:00

Entering the golden age for antibody-drug conjugates in gynecologic cancer

“We are optimistic that the incorporation of ADCs into the treatment of aggressive tumors and treatment refractory gynecologic cancers will improve quality of life and survival outcomes in our patients.”

Oncoscience

Credit: 2024 Greenman et al.

BUFFALO, NY- July 12, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Entering the golden age for antibody-drug conjugates in gynecologic cancer.”

In this new editorial, researchers Michelle Greenman, Blair McNamara, Levent Mutlu, and Alessandro D. Santin from Yale University School of Medicine discuss gynecologic cancers. Biologically aggressive tumors such as uterine serous carcinoma (USC) and carcinosarcoma (CS) are aggressive subtypes of endometrial cancer with a poor prognosis and a disproportionately high mortality rate.

“Cytoreductive surgery along with chemotherapy is critical in treatment.”

However, recurrence is common, requiring multiple lines and combinations of chemotherapy. Use of immunotherapy in combination with gold standard chemotherapy regimens and targeted drugs represent novel modalities in treatment endowed with a remarkable potential in endometrial cancer patients. In a recent publication, entitled “In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma” the researchers evaluated trastuzumab-deruxtecan (T-DXd), a HER2-directed antibody drug conjugate (ADC) against biologically aggressive uterine tumors.

“We demonstrated for the first time the remarkable preclinical activity of T-DXd against primary USC cells lines as well as USC xenografts overexpressing HER2/neu.”

Continue reading: DOI: https://doi.org/10.18632/oncoscience.604

Correspondence to: Alessandro D. Santin

Email: alessandro.santin@yale.edu

Keywords: antibody-drug conjugates, gynecologic malignancies, precision medicine

About Oncoscience:

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media: